NasdaqGS:WBD
NasdaqGS:WBDEntertainment

How the Latest Price Target Cut Impacts Warner Bros. Discovery’s Investment Appeal in 2025

If you are wrestling with what to do about Warner Bros. Discovery stock right now, you are not alone. After a rocky few years, WBD has staged a notable comeback, with shares up over 50% in the last year. Despite a dip of nearly 10% in the past month and a recent price target cut from Raymond James, analysts still seem optimistic about longer-term potential. This sentiment comes as the company navigates challenging industry shifts, such as recent layoffs and evolving content strategies. Some...
NYSE:NEU
NYSE:NEUChemicals

Could NewMarket’s (NEU) Strong Dividend and Reinvestment Approach Reveal Its Capital Allocation Priorities?

On August 7, 2025, the Board of Directors of NewMarket Corporation declared a quarterly dividend of US$2.75 per share, payable October 1, 2025, to shareholders of record as of September 15, 2025. Unique among its peers, NewMarket's strong return on equity, currently around 30%, has been matched by above-average net income growth and robust earnings reinvestment strategies. We’ll now explore how NewMarket’s ongoing reinvestment of profits shapes its investment narrative in light of its...
NasdaqGS:IRTC
NasdaqGS:IRTCMedical Equipment

The Bull Case for iRhythm Technologies (IRTC) Could Change Following Landmark Real-World Study of Zio LTCM

iRhythm Technologies announced that a large real-world study published in the American Journal of Managed Care found its Zio® long-term continuous monitoring (LTCM) service outperformed other ambulatory cardiac monitoring methods in clinical outcomes, diagnostic speed, and healthcare cost reduction for commercially insured adults in the U.S. This publication expands on prior findings in Medicare patients and highlights the value of Zio LTCM with the highest rate of new arrhythmia diagnoses,...
NYSE:UBER
NYSE:UBERTransportation

Is Now the Right Moment to Consider Uber After Its 48% Rally in 2025?

Thinking about what to do with Uber Technologies stock? You are not alone. With the share price recently closing at $93.73, Uber continues to catch investors’ attention in a big way. The watercooler conversations have only picked up as the stock has delivered a 48% gain year-to-date and climbed over 2,200% in the last three years. While there was a slight slip of about 1.7% yesterday, it has mostly been a story of steady gains and improving sentiment over the past few months. What is driving...
NYSE:WTM
NYSE:WTMInsurance

Is White Mountains Insurance Group's Return to Profit Reshaping Its Investment Appeal (WTM)?

White Mountains Insurance Group previously reported its second quarter 2025 results, with revenue rising to US$689.2 million and net income turning to US$122.9 million from a net loss a year before. This reflects a strong reversal in performance for the quarter, as basic and diluted earnings per share moved into positive territory from prior-year losses. We will explore how the company’s shift from a quarterly net loss to net profit shapes its investment narrative moving forward. AI is about...
NYSE:SNAP
NYSE:SNAPInteractive Media and Services

Is Snap Ready for a Turnaround After a 28% Drop This Month?

If you have ever debated whether now is the right moment to buy, sell, or simply hold onto Snap stock, you are definitely not alone. The past year has been a wild ride for Snap’s share price. After peaking hopes, the stock has dropped about 24% over the past 12 months and is down more than 66% across five years. Most recently, shares closed at $7.16, off nearly 28% in just the past month. Investors are searching for answers, especially as swings in social media stocks keep hitting the...
NasdaqCM:LQDA
NasdaqCM:LQDAPharmaceuticals

Will Liquidia's (LQDA) Revenue Growth Offset Concerns About Widening Losses and Operational Efficiency?

On August 12, 2025, Liquidia Corporation reported its second quarter and six-month financial results, revealing revenue growth to US$8.84 million and US$11.96 million respectively, but wider net losses of US$41.58 million for the quarter and US$79.95 million for the half-year. This report highlighted a significant surge in revenue year-over-year, even as net losses and per-share losses increased compared to the previous periods. We'll examine how Liquidia's increased revenue amid a larger...
NasdaqGS:AFRM
NasdaqGS:AFRMDiversified Financial

Affirm (AFRM): Exploring Valuation After Recent Stock Volatility and Strong Gains

Affirm Holdings (AFRM) has just delivered a move that is likely to spark debate among investors wondering what comes next. The stock saw a sudden shift, dipping about 1% in the most recent session. This comes after a month marked by significant swings, including a jump of more than 9%. There is no headline event or breaking development driving today’s price action. Sometimes these quieter stretches are where signals hide in plain sight, raising the real question of whether the market is...
NYSE:VST
NYSE:VSTRenewable Energy

Assessing Vistra’s Value After 136% Surge and Data Center Expansion News

If you’ve been tracking Vistra lately, you know it’s been anything but boring. Maybe you’re wondering if now is the time to buy, sell, or sit tight on your shares, or if you’re missing out on a rising star. Over the past year, Vistra’s stock has surged by more than 136%, delivering eye-popping gains compared to the broader utility sector. The climb isn’t just a short-term story either, with the 3-year and 5-year returns at roughly 710% and over 1,050%, respectively. That kind of performance...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

What Incyte (INCY)'s Q2 Revenue Beat and Product Growth Mean for Shareholders

In the past quarter, Incyte delivered exceptional results with revenues exceeding analysts’ estimates by 9.1%, fueled by robust growth in Jakafi®, Opzelura®, and Niktimvo™. This performance highlights not only Incyte’s strong momentum in the immuno-oncology space, but also broader sector strength as peers like Regeneron, Natera, and Exact Sciences similarly surpassed expectations. We’ll now explore how Incyte’s Q2 revenue outperformance and product growth could influence its long-term...
NasdaqGS:GFS
NasdaqGS:GFSSemiconductor

How the Recent 28% Drop Shapes the Outlook for GlobalFoundries in 2025

Thinking about what to do with GlobalFoundries stock? You are not alone. GFS has kept investors on their toes lately, thanks to a string of notable price movements and a valuation that is catching savvy eyes. Over the past year, shares have tumbled nearly 28%, and the year-to-date drop stands at 22%. Even over the past ninety days, GFS is down nearly 12%. This pattern of declines has shifted perceptions around GlobalFoundries, with current sentiment landing somewhere between cautious...
NasdaqGS:RIVN
NasdaqGS:RIVNAuto

Rivian (RIVN): Examining Valuation After the Latest Stock Slide

If you follow Rivian Automotive (RIVN), the recent dip in the company’s stock price may have caught your eye. Shares have slid over 11% in the past month, continuing a downward trend that has sparked questions about how the market is weighing Rivian’s growth prospects against new risks. While no single headline caused the move, the decline is attracting investors who are re-examining what is currently being priced in for this electric vehicle maker. This latest slide follows a year marked by...
NYSE:CFG
NYSE:CFGBanks

Citizens Financial Group (CFG): Assessing Valuation After Appointing New CFO With Global Banking Experience

When a major leadership change hits a financial institution, investors naturally tune in. Citizens Financial Group (CFG) just announced that Aunoy Banerjee, currently CFO at Barclays Bank PLC, will take over as its new Chief Financial Officer this fall. Banerjee brings deep experience from major players like Barclays, State Street, and Citi. He will step in after outgoing CFO John Woods departs, with interim CFO Chris Emerson serving in the role until Banerjee’s arrival. For a bank of...
NYSE:BMY
NYSE:BMYPharmaceuticals

What Do New Tariff Talks Mean for Bristol-Myers Squibb’s Share Price in 2025?

Trying to decide what to do with Bristol-Myers Squibb stock? You are not alone. The big pharma name, with its deep pipeline and decades-long track record, has had a rocky road lately, but there are hints that the story could be changing. Over the past month, shares have climbed over 3%, and it looks like investors are starting to price in both new risks and fresh opportunities around the company. Much of this movement has followed ongoing talk out of Washington about pharmaceutical tariffs...
NasdaqGS:GEHC
NasdaqGS:GEHCMedical Equipment

GE HealthCare Technologies (GEHC): Is the Stock’s Quiet Slide Creating an Undervalued Opportunity?

GE HealthCare Technologies (GEHC) has recently drawn attention as its stock edged lower following a quiet stretch for headline news. While no single event sparked the move, some investors are now taking a closer look, wondering if the shift is an early signal for deeper value or simply a reflection of shifting sentiment in the broader healthcare sector. With the conversation around healthcare innovation heating up lately, this subtle change might be enough to nudge GE HealthCare Technologies...
NasdaqGS:WDC
NasdaqGS:WDCTech

Is There Opportunity in Western Digital After 51% Rally and Toshiba Merger Progress in 2025?

If you are weighing whether to buy, hold, or sell Western Digital stock right now, you are not alone. This storied data storage giant has been on a bit of a rollercoaster lately, capturing the attention of both risk-tolerant growth seekers and valuation-minded investors. Over the last three months, Western Digital shares have surged over 51%, and the stock price is up an impressive 54% over the past year. If you zoom out to three or five years, returns have more than doubled and nearly...
NYSE:POST
NYSE:POSTFood

What Post Holdings (POST)'s Earnings Growth and Leadership Change Mean for Shareholders

Post Holdings reported third-quarter earnings with sales of US$1.98 billion and net income of US$108.8 million, both showing increases from the same period last year; the company also completed a significant tranche of its share repurchase program and announced upcoming leadership changes, with Nicolas Catoggio named as the next Chief Operating Officer. The simultaneous announcement of leadership succession and a completed share buyback signals both operational continuity and management’s...
NYSE:CAH
NYSE:CAHHealthcare

Did Cardinal Health’s (CAH) Rising Profits Amid Lower Sales Just Shift Its Investment Narrative?

Cardinal Health recently announced several updates, including its Board of Directors approving a quarterly dividend of US$0.5107 per share and the completion of a US$599.45 million fixed-income offering, alongside reporting a substantial increase in net income to US$1.56 billion for the full year ended June 30, 2025 despite a decrease in sales. Profitability gains stood out, with basic earnings per share from continuing operations rising to US$6.48, reflecting improved operational...
NasdaqGS:EBAY
NasdaqGS:EBAYMultiline Retail

A Fresh Look at eBay (EBAY) Valuation After Recent Stock Surge

eBay (EBAY) has quietly caught investor attention this month, with shares climbing nearly 25% after moving mostly sideways for much of the year. There is not a single headline event driving this recent surge, which may leave many shareholders wondering if the wider market is finally reconsidering eBay’s value, or if a shift in sentiment is underway beneath the surface. Sometimes, when stocks move without a big news catalyst, it can be a sign that expectations for future growth or risk have...
NYSE:LH
NYSE:LHHealthcare

FDA-Cleared Blood Test for Alzheimer’s Might Change the Case for Investing in Labcorp (LH)

Labcorp recently announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood-based in-vitro diagnostic test to aid in the diagnosis of Alzheimer's disease in appropriate patients, developed by Fujirebio Diagnostics Inc. This launch offers a more accessible and less invasive alternative to traditional Alzheimer's diagnostics, coinciding with new clinical guidelines that endorse blood-based biomarkers for evaluating cognitive...
NasdaqGS:CHKP
NasdaqGS:CHKPSoftware

Does Check Point's Elevated P/E Ratio Signal Confidence or Risk for CHKP’s Long-Term Growth Story?

In recent days, concerns have grown among Check Point Software Technologies Ltd. shareholders regarding the company's elevated price-to-earnings (P/E) ratio of 23.6x, which stands out compared to many US companies. This focus has intensified as analysts project slower-than-market-average earnings growth over the next three years, prompting questions about whether the company's valuation is sustainable. We'll explore how worries about the high P/E ratio and slower earnings growth influence...
NasdaqGM:ENPH
NasdaqGM:ENPHSemiconductor

Does Enphase Offer Value After Its 70% Drop and Recent Cash Flow Growth?

If you’ve been watching Enphase Energy stock lately, you know just how lively this ticker can get. Whether you’re thinking of doubling down or nervously eyeing your portfolio, ENPH has kept investors on their toes. Over the past month, the stock dipped about 10%, with a 70% drop over the last year, making even long-term holders take a second look. Yet, short-term momentum is showing a bit more pep, climbing around 4% over the last week. All this volatility often reflects big changes in how...